By Rory McCann, Marketing Manager & Conference Producer, LSN
One of the most active sectors in longevity and aging is drug discovery and development. Life Science Nation (LSN) is pleased to introduce the early-stage therapeutics panel at LSN’s newest partnering conference, Longevity, Health & Innovation (LHI). Led by Anastasiya Giarletta, a Principal at R42 Group, the panel will discuss the latest trends in the marketplace that impact how investors source and vet novel therapeutic assets and how today’s climate impacts their strategy to move these necessary products to commercialization. Get to know the panelists and sign up for Longevity, Health & Innovation to begin partnering with investors who match your product and stage of development.
Moderator： Anastasiya Giarletta, Principal, R42 Group
Anastasiya Giarletta manages an extensive business network spanning FinTech, artificial intelligence and rapidly growing longevity biotech industries in the UK, Silicon Valley and New York. As a specialist in the early-stage longevity biotech ecosystem, she connects and advises venture funds, angels, and entrepreneurs, aligning them with success and growth, as well as organizing and leading collaborative longevity biotech industry events with her company Aikora Health. Previously, Anastasiya’s focus was on financial services, FinTech and venture capital space. Anastasiya holds a degree in Management and Sustainable Development from the University of St Andrews.
Alexandra Bause, Partner, Apollo Ventures
Alexandra is leading the venture creation programs that aim at founding new biotech startups targeting the aging process at a molecular level. She is also managing the pipeline and diligence process for external investment opportunities, predominantly focusing on preclinical stage biotech companies. Before joining Apollo Ventures, Alexandra worked with The Boston Consulting Group where she specialized in biopharma strategy, market assessment and asset diligence. Her PhD studies at Harvard Medical School were focused on investigating the molecular mechanisms that contribute to cellular aging and could be targeted to increase mammalian health span. She is also a trained pharmacist with expertise in pharmaceutics and pharmacology.
Patrick Burgermeister, Partner, KIZOO Technology Capital
Patrick Burgermeister is an expert in life science investing with a double background in molecular biology (Biozentrum Basel) and business administration (HSG Sankt Gallen). He joined Kizoo in 2019 coming from the venture capital group BioMedPartners where he was one of the partners. Moreover, his industry career encompasses also banking (as a senior analyst for pharma/biotech) and pharma (as a senior portfolio manager at Novartis). Patrick supports various biotech companies as a director on their boards, was a successful business developer for early-stage biotech companies and led collaboration and licensing deals with public and private companies. He headed business development at several companies including Apeiron Biologics and BioVersys.
Sergey Jakimov, Executive Board Member, Longenesis
Sergey Jakimov is a founder and advisor to multiple growth-stage startups in Europe and Asia. His main field of expertise is the industrial integration of digital health solutions and novel biomedical technologies, as well as the commercialization of hard IP assets. After graduating with merit from Central European University and Riga Graduate School of Law, Sergey founded two deep-tech ventures, one of which – Koatum – is a biomedical technology company that develops targeted drug delivery systems for dental and orthopedic implants, that is currently in the last round of validation before being launched as a commercial product into the US market. Using his experience in the field, Sergey, as the CEO of Longenesis – a digital health tech company, provides the R&D industry with tools that facilitate the clinical trial process in multiple research and healthcare institutions around the globe. Sergey is also a guest lecturer and co-author of the study program on product commercialization at the University of Latvia, as well as a guest lecturer in Riga Graduate School of Law (Latvia) and Riga Stradins University (Latvia). Recently, Sergey has co-founded LongeVC – an early-stage longevity-focused VC fund, looking to back emerging longevity tech in seed and pre-A stages.
Joon Yun, MD, President & Partner, Palo Alto Investors
Dr. Joon Yun is President and Managing Partner of Palo Alto Investors LP, a healthcare hedge fund founded in 1989. Board-certified in radiology, Joon served on the clinical faculty at Stanford from 2000-2006. Joon has served on numerous boards, and he is currently a trustee of the Salk Institute. Joon is a member of the President’s Circle of the National Academies of Sciences, Engineering, and Medicine. Joon has published dozens of patents and scientific articles. Joon and his wife Kimberly launched the $1 million Palo Alto Longevity Prize in 2013 to reverse the aging process and recently donated $2 million to launch the National Academy of Medicine Aging and Longevity Grand Challenge. Fun fact: Joon has been going to Burning Man consecutively for the past 18 years.
If you’re looking for increased exposure and opportunities to pitch directly to investors at LHI, look no further than the Innovator’s PItch Challenge (IPC). Start-ups can pitch directly to a panel of investors during a live Q&A session. These sessions will provide valuable insights and feedback, as well as build connections between fundraising founders and potential strategic partners. Each company will be provided with a dedicated landing page on LHI’s virtual agenda, which will include their 4-minute pre-recorded pitch video, slide deck, executive summary, etc. Click here to learn more and apply for LHI’s Innovator’s Pitch Challenge.
